Dose calculation of anticancer drugs

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2008-09-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/17425255.4.10.1307PMID 18798700
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of gefitinib in the management of Asian patients with non-small cell lung cancer.

  2008cited by this paper
• Potential regional differences for the tolerability profiles of fluoropyrimidines.

  2008cited by this paper
• Lifestyle habits as a contributor to anti-cancer treatment failure.

  2008cited by this paper
• Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey.

  2008cited by this paper
• The role of gefitinib in the management of Asian patients with non-small cell lung cancer

  2008cited by this paper
• Inflammation and Altered Drug Clearance in Cancer: Transcriptional Repression of a Human CYP3A4 Transgene in Tumor‐bearing Mice

  2008cited by this paper
• Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

  2008cited by this paper
• Obesity in dose calculation: a mouse or an elephant?

  2007cited by this paper
• Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics

  2007cited by this paper
• Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer.

  2007cited by this paper
• Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

  2007cited by this paper
• Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.

  2007cited by this paper
• Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.

  2007cited by this paper
• Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

  2007cited by this paper
• Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

  2007cited by this paper
• Chemotherapy dosing part I: scientific basis for current practice and use of body surface area.

  2007cited by this paper
• Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype

  2007cited by this paper
• UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

  2007cited by this paper
• Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.

  2006cited by this paper
• PAC Fixed Dose: Pharmacokinetics of a 1-Hour Paclitaxel Infusion and Comparison to BSA-Normalized Drug Dosing

  2006cited by this paper
• Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

  2006cited by this paper
• Developing a new framework for dose calculation.

  2006cited by this paper
• Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.

  2006cited by this paper
• Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

  2006cited by this paper
• Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

  2006cited by this paper
• Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.

  2006cited by this paper
• Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer

  2006cited by this paper
• A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer

  2006cited by this paper
• Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors

  2005cited by this paper
• I don't underdose my patients...do I?

  2005cited by this paper
• Accuracy, feasibility and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high‐dose chemotherapy

  2005cited by this paper
• Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls.

  2005cited by this paper
• Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

  2005cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.

  2005cited by this paper
• Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

  2005cited by this paper
• Pharmacokinetic variability of anticancer agents

  2005cited by this paper
• THE CLASSIC: Amputation and Adriamycin in Primary Osteosarcoma

  2005cited by this paper
• Hepatic Technetium Tc 99m–labeled Sestamibi Elimination Rate and ABCB1 (MDR1) Genotype as Indicators of ABCB1 (P–glycoprotein) Activity in Patients with Cancer

  2005cited by this paper
• Capecitabine: a review.

  2005cited by this paper
• Glucuronidation and the UDP-glucuronosyltransferases in health and disease.

  2004cited by this paper
• Probing the world of cytochrome P450 enzymes.

  2004cited by this paper
• Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue

  2004cited by this paper
• Prospective Evaluation of Body Surface Area as a Determinant of Paclitaxel Pharmacokinetics and Pharmacodynamics in Women with Solid Tumors

  2004cited by this paper
• Flat-Fixed Dosing of Irinotecan

  2004cited by this paper
• Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation

  2004cited by this paper
• Evidence for the Benefits of the Low-Molecular-Weight Heparin Dalteparin in ‘High-Risk’ Patients with Acute Coronary Syndromes

  2004cited by this paper
• Effect of St John's Wort on imatinib mesylate pharmacokinetics

  2004cited by this paper
• Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy

  2004cited by this paper
• Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer

  2004cited by this paper
• Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

  2004cited by this paper
• Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.

  2003cited by this paper
• The camptothecins.

  2003cited by this paper
• Targeted filgrastim support in patients with early‐stage breast carcinoma

  2003cited by this paper
• How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?

  2003cited by this paper
• Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.

  2002cited by this paper
• High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.

  2002cited by this paper
• Getting the right dose in cancer chemotherapy – time to stop using surface area?

  2002cited by this paper
• Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil.

  2002cited by this paper
• Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene

  2002cited by this paper
• Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

  2002cited by this paper
• First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.

  2002cited by this paper
• Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs

  2002cited by this paper
• The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.

  2002cited by this paper
• Body surface area in dosing anticancer agents: scratch the surface!

  2002cited by this paper
• Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

  2002cited by this paper
• Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy.

  2001influential reference
• Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.

  2001cited by this paper
• Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.

  2001cited by this paper
• Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing

  2001cited by this paper
• Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

  2000cited by this paper
• Optimizing the erythromycin breath test for use in cancer patients.

  2000cited by this paper
• Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia

  2000cited by this paper
• Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case.

  2000cited by this paper
• The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.

  2000cited by this paper
• Problems and perspectives of phenotyping for drug-metabolizing enzymes in man.

  2000cited by this paper
• Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

  2000cited by this paper
• Pharmacokinetically Guided Administration of Chemotherapeutic Agents

  2000cited by this paper
• Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.

  1999cited by this paper
• Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.

  1999cited by this paper
• Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

  1999cited by this paper
• Can Pharmacokinetic Monitoring Improve Clinical Use of Fluorouracil?

  1999cited by this paper
• Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

  1998cited by this paper
• Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

  1998cited by this paper
• New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors.

  1998cited by this paper
• Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.

  1998cited by this paper
• Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach.

  1998cited by this paper
• Practical Treatment Guide for Dose Individualisation in Cancer Chemotherapy

  1998cited by this paper
• Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer

  1998cited by this paper
• Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

  1998cited by this paper
• Use of Probe Drugs as Predictors of Drug Metabolism in Humans

  1997cited by this paper
• Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.

  1997cited by this paper
• Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.

  1997cited by this paper
• Validation of the five‐drug “Pittsburgh cocktail” approach for assessment of selective regulation of drug‐metabolizing enzymes

  1997cited by this paper
• Pharmacology of cancer chemotherapy in the older person.

  1997cited by this paper
• Pharmacokinetic Optimisation of Cancer Chemotherapy

  1997cited by this paper
• A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

  1996cited by this paper
• A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation

  1996cited by this paper
• Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.

  1996cited by this paper
• Predicting etoposide toxicity: relationship to organ function and protein binding.

  1996cited by this paper

• Cell‐Free and Concentrated Ascites Reinfusion Therapy (CART) Shows Enhanced Efficacy in Gynecological Cancer Patients: A Post‐Marketing Surveillance Study

  2025cites this paper
• Body Composition in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease: Impact of Body Surface Area

  2024cites this paper
• Phenotype versus genotype to optimize cancer dosing in the clinical setting—focus on 5‐fluorouracil and tyrosine kinase inhibitors

  2024cites this paper
• Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials

  2023cites this paper
• Image-analysis based readout method for biochip: Automated quantification of immunomagnetic beads, micropads and patient leukemia cell.

  2020cites this paper
• Carboplatin dosing in real life: Beyond estimating glomerular filtration rate and the virtue of simplicity!

  2019cites this paper
• Epidemiology A Bayesian Sensitivity Analysis to Partition Body Mass Index Into Components of Body Composition: An Application to Head and Neck Cancer Survival

  2019cites this paper
• A Bayesian Sensitivity Analysis to Partition BMI Into Components of Body Composition: An Application to Head and Neck Cancer Survival.

  2019cites this paper
• Modélisation et quantification 3D de la taille des superficies corporelles brûlées

  2019cites this paper
• Ultra-High-Precision, in-vivo Pharmacokinetic Measurements Highlight the Need for and a Route Toward More Highly Personalized Medicine

  2019cites this paper
• Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients

  2018cites this paper
• Predicting drug delivery efficiency into tumor tissues through molecular simulation of transport in complex vascular networks

  2018cites this paper
• Quantification of DNA double-strand breaks in peripheral blood mononuclear cells from healthy donors exposed to bendamustine by an automated γH2AX assay—an exploratory study

  2018cites this paper
• Dose Determination for Hydrophilic and Lipophilic Drugs for Chemotherapy and Immunotherapy

  2018cites this paper
• Closed-loop control of circulating drug levels in live animals

  2017cites this paper
• Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy

  2017cites this paper
• A Cost Saving and Waste Minimization Study About Handling of the Antineoplastic Agents

  2017cites this paper
• Tolerability of a rapid‐escalation vinblastine‐prednisolone protocol in dogs with mast cell tumours

  2016cites this paper
• Anatomical and physiological basis for the allometric scaling of cisplatin clearance in dogs.

  2016cites this paper
• Computational oncology — mathematical modelling of drug regimens for precision medicine

  2016cites this paper
• Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect

  2016cites this paper
• Individuelle Dosisanpassung durch Therapeutisches Drug Monitoring

  2016cites this paper
• Standardisation des doses (ou "Dose-Banding") des médicaments injectables : application à deux principes actifs l'aciclovir et l'infliximab

  2016cites this paper
• Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?

  2016cites this paper
• Species differences in tumour responses to cancer chemotherapy

  2015cites this paper
• Impact of outpatient interventions made at an ambulatory cancer centre oncology pharmacy in Singapore

  2015cites this paper
• Standardization and Scoring of the Body Surface Area (BSA) Formulas for Calculation of the Doses of Anticancer Agents for Cancer Patients from the North-Western Nigeria

  2015cites this paper
• Clinical Pharmacology in Pediatrics

  2014cites this paper
• Defining the Starting Dose: Should It Be mg/kg, mg/m2, or Fixed?

  2014cites this paper
• Indexing Glomerular Filtration Rate to Body Surface Area: Clinical Consequences

  2014cites this paper
• Intra-patient dose escalation in Ewing’s sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review

  2013cites this paper
• Determination of half maximal inhibitory concentration (IC50) of several anticancer drugs for inhibiting CYP3A4 metabolism of midazolam

  2012cites this paper
• Measures of Body Surface Area in Children

  2012cites this paper
• The role of nutrition on effectiveness of chemotherapy

  2012cites this paper
• Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese Adults

  2012cites this paper
• Hurdles in anticancer drug development from a regulatory perspective

  2012cites this paper
• Increased cerebral oxidative damage and decreased antioxidant defenses in ovariectomized and sham-operated rats supplemented with vitamin A

  2012cites this paper
• Evidence for therapeutic drug monitoring of targeted anticancer therapies.

  2012cites this paper
• Pharmacodynamic Modeling of Vincristine in Lymphoma Patients

  2011cites this paper
• Dosing done right: a review of common chemotherapy calculations.

  2011cites this paper
• Moving towards dose individualization of tyrosine kinase inhibitors.

  2011cites this paper
• Pharmacodynamic Evaluation: Oncology

  2011cites this paper
• Irinogenetics: how many stars are there in the sky?

  2009cites this paper
• Digital Commons@Becker Digital Commons@Becker

  year unknowncites this paper